PAOLO ALBERTO PACIUCCI, M.D.; NANCY T. SKLARIN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The use of mitoxantrone as an antineoplastic drug was reviewed recently by Shenkenberg and Von Hoff (1), who described its biochemistry, pharmacology, activity, and associated toxicities. Since 1979 we have investigated mitoxantrone extensively in the treatment of acute leukemias, lymphomas, and breast carcinomas. We have noted a toxicity that the reviewers failed to mention, hepatotoxicity.
In our study (2) of 26 patients with primarily refractory or relapsed acute lymphocytic leukemia, acute myelocytic leukemia, and blastic phase chronic myelocytic leukemia, mitoxantrone was given alone at a dosage of 8 to 20 mg/m2 body surface area intravenously daily for
PACIUCCI PA, SKLARIN NT. Mitoxantrone and Hepatic Toxicity. Ann Intern Med. ;105:805–806. doi: 10.7326/0003-4819-105-5-805_3
Download citation file:
Published: Ann Intern Med. 1986;105(5):805-806.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use